GlassScriptPhysician profile
Ileana R Perez
NPI 1205886033
$4,038.81
in general payments reported to CMS, 2019-2025
31 companies · $814 in 2025
The $814 reported for 2025 was more than what 89% of Obstetrics providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $873 · 2020: $612 · 2021: $639 · 2022: $185 · 2023: $617 · 2024: $301 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,646 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,645.99 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gynesonics, INC. | $604.12 | 2020-2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Hologic Sales and Service, LLC | $503.17 | 2021-2025 | Aptima, Thinprep 2000 Processor, Novasure |
| Abbvie INC. | $399.50 | 2019-2022 | |
| Merz North America, INC. | $300.00 | 2019 | |
| Astellas Pharma US INC | $275.67 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $271.24 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $203.08 | 2019-2025 | |
| Pfizer INC. | $145.05 | 2022-2024 | |
| Allergan, INC. | $144.68 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $140.67 | 2019-2025 | Jublia, Arazlo, Cabtreo |
| Revance Therapeutics, INC. | $121.08 | 2025 | Daxi |
| Covidien LP | $97.19 | 2019 | |
| Sumitomo Pharma America, INC. | $95.88 | 2023-2024 | Myfembree |
| Organon LLC | $93.25 | 2024-2025 | |
| Myovant Sciences INC. | $76.21 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $74.19 | 2025 | Zurzuvae |
| Coopersurgical, INC. | $71.38 | 2019-2024 | Paragard T 380a |
| Millicent US INC | $66.14 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Evofem Biosciences, INC. | $60.53 | 2024-2025 | Phexxi, Solosec, Phexx |
| Channel Medsystems, INC. | $47.28 | 2023 | |
| Exeltis, USA INC. | $44.48 | 2024-2025 | Slynd |
| Epi Health, LLC | $44.00 | 2019 | |
| Mylan Pharmaceuticals INC. | $21.74 | 2020 | |
| Aclaris Therapeutics, INC. | $21.53 | 2019 | |
| Becton, Dickinson and Company | $19.97 | 2024 | Bd Onclarity |
| Novo Nordisk INC | $18.89 | 2023 | Wegovy |
| Therapeuticsmd, INC. | $18.51 | 2020 | |
| Botanix Sb INC | $17.76 | 2025 | Sofdra |
| Meditrina | $14.62 | 2025 | |
| Duchesnay USA Incorporated | $13.72 | 2019 | |
| Medicem INC. | $13.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ileana Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.